MedPath

Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses

Completed
Conditions
Autism Spectrum Disorder
Registration Number
NCT03971578
Lead Sponsor
Intelligent Hearing Systems
Brief Summary

The purpose of this study is to develop an Auditory Brainstem Response (ABR) based neurological screening method to detect increased risk for Autism Spectrum Disorders (ASD) and other neurological conditions in newborns.

Detailed Description

In the proposed study, a screening method for neurological deficits, with an emphasis on its application to ASD, will be developed and its feasibility demonstrated. The proposed method will utilize high rate stimulation to acquire Auditory Brainstem Responses in order to determine peak latency and amplitude differences in children with ASD compared to non-ASD. Similarly to newborn hearing screening, the output of the screening method will provide an automated pass or refer outcome that can be used by a physician to determine if the child needs further evaluation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
81
Inclusion Criteria
  • Children with autism spectrum disorder diagnosis
  • Normally developing age- and gender-matched controls
Exclusion Criteria
  • Permanent or temporary hearing loss at the time of testing.
  • Craniofacial abnormalities

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ABR Peak V LatencyOne Week

Auditory Brainstem Response (ABR) peak V latency measurement for the five stimulation rates used in the study. The latency is the time, measured in ms, from the onset of the stimulus to the generation of the response peak component. ABR peak V is the most prominent response peak component in humans.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Miami Department of Psychology

🇺🇸

Coral Gables, Florida, United States

University of Miami Department of Psychology
🇺🇸Coral Gables, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.